I like these numbers but I have my reservations around how the prospect of further dilution in the months ahead will affect the SP.
If the FDA Type B meetings confirms the need for two well-controlled trials, Invex will be forced to consider whether another capital raising to run an additional trial is worth securing the FDA registration.
Given the laggard share price, my feeling is that the market is expecting the FDA to ask for 2 trials and Invex being forced into another capital raising to fund a second trial to satisfy the FDA registration.
They could go alone on one trial and secure EMA registration only, but given they want a buyout, it'll reduce their valuation by around half without the FDA.
- Forums
- ASX - By Stock
- IXC
- Ann: Investor Presentation
Ann: Investor Presentation, page-18
-
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.260M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 23 | 7.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 8695 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 23 | 0.072 |
2 | 84853 | 0.070 |
1 | 100000 | 0.063 |
1 | 100000 | 0.062 |
2 | 158500 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 8695 | 1 |
0.079 | 30837 | 1 |
0.080 | 19000 | 2 |
0.083 | 4000 | 1 |
0.090 | 126146 | 1 |
Last trade - 10.04am 15/08/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online